X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ACTAVIS (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   ACTAVIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ACTAVIS
Dec-14
TORRENT PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,76817,533-   
Low Rs1,18610,695-   
Sales per share (Unadj.) Rs346.13,157.2-  
Earnings per share (Unadj.) Rs55.2-394.0-  
Cash flow per share (Unadj.) Rs73.3289.7-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.16,847.8-  
Shares outstanding (eoy) m169.22265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.5 95.4%   
Avg P/E ratio x26.8-35.8 -74.7%  
P/CF ratio (eoy) x20.148.7 41.3%  
Price / Book Value ratio x5.72.1 278.7%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8873,752,831 6.7%   
No. of employees `00011.821.6 54.5%   
Total wages/salary Rs m9,9340-   
Avg. sales/employee Rs Th4,971.538,865.5 12.8%   
Avg. wages/employee Rs Th843.20-   
Avg. net profit/employee Rs Th792.4-4,850.0 -16.3%   
INCOME DATA
Net Sales Rs m58,569839,495 7.0%  
Other income Rs m2,233-2,095 -106.6%   
Total revenues Rs m60,802837,400 7.3%   
Gross profit Rs m13,773107,845 12.8%  
Depreciation Rs m3,069181,781 1.7%   
Interest Rs m2,05626,479 7.8%   
Profit before tax Rs m10,881-102,511 -10.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,520 0.0%   
Tax Rs m1,545-5,270 -29.3%   
Profit after tax Rs m9,336-104,760 -8.9%  
Gross profit margin %23.512.8 183.0%  
Effective tax rate %14.25.1 276.2%   
Net profit margin %15.9-12.5 -127.7%  
BALANCE SHEET DATA
Current assets Rs m53,841442,306 12.2%   
Current liabilities Rs m31,612322,571 9.8%   
Net working cap to sales %38.014.3 266.1%  
Current ratio x1.71.4 124.2%  
Inventory Days Days9758 167.5%  
Debtors Days Days8466 126.4%  
Net fixed assets Rs m42,079102,511 41.0%   
Share capital Rs m8460-   
"Free" reserves Rs m42,6550-   
Net worth Rs m43,5011,820,833 2.4%   
Long term debt Rs m22,408954,152 2.3%   
Total assets Rs m101,2503,336,988 3.0%  
Interest coverage x6.3-2.9 -219.2%   
Debt to equity ratio x0.50.5 98.3%  
Sales to assets ratio x0.60.3 229.9%   
Return on assets %11.3-2.3 -479.6%  
Return on equity %21.5-5.8 -373.0%  
Return on capital %19.6-3.0 -651.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,7620-   
CASH FLOW
From Operations Rs m10,127144,158 7.0%  
From Investments Rs m-7,869-345,168 2.3%  
From Financial Activity Rs m-1,918193,935 -1.0%  
Net Cashflow Rs m212-7,076 -3.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: IPCA LABS  DIVIS LABORATORIES  ALEMBIC PHARMA  GLENMARK PHARMA  NATCO PHARMA  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - UNICHEM LAB COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS